# Regeneron Pharmaceuticals, Inc.  Share Price Target ‘$1,016.86’, now 8.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc.share-price-target-1016.86-now-8.4-upside-potential/4121142078
- Published: 2024-02-09T15:11:03+00:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** which can be found using ticker (REGN) have 
now 22 confirmed analysts covering the stock with the consensus suggesting a rating
of ‘buy’. The target price High/Low ranges between $1,152.00 and $710.00 with the
average share target price sitting at $1,016.86. (at the time of writing). Given
that the stocks previous close was at $938.49 this now indicates there is a potential
upside of 8.4%. Also worth taking note is the 50 day moving average now sits at 
$892.96 while the 200 day moving average is $810.65. The company has a market cap
of 103.88B. The current share price for the company is: $946.43 USD

 The potential market cap would be $112,556,872,006 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 27.23, revenue per share of $122.94
and a 8.49% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on: